Compare ResMed Inc. (RMD) vs Teladoc Health Inc (TDOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Teladoc Health Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Teladoc Health Inc trades at $6.09 (market cap $1.14B). The key difference: ResMed Inc. is far larger — about 28× Teladoc Health Inc's market cap, and ResMed Inc. pays a 1.19% dividend while Teladoc Health Inc pays none. Which is the better fit depends on your goals.
| RMD | TDOC | |
|---|---|---|
Market Cap | $31.89B | $1.14B |
Sector | Health | Health |
52-Week High | $283.28 | $9.72 |
52-Week Low | $182.82 | $4.47 |
Enterprise Value | $31.24B | $1.40B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
TDOC trades at $6.26, down 0.32% on the day, with a bearish technical signal and neutral oscillators. The company reported a net loss of $200.32 million in 2025, though revenue remains stable at $2.53 billion. Recent news includes the appointment of a new CFO and ongoing legal investigations, while analyst consensus is a $8.88 price target with a hold-heavy rating.
The outlook is mixed: valuation metrics like P/S of 0.45 and EV/EBITDA of 6.5 suggest potential undervaluation, but persistent losses and negative cash flow in 2025 pose risks. Upside hinges on profitability improvements from its integrated care segment, while competitive pressures and weak BetterHelp performance are headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →
